ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Data demonstrate the potential of ElevateBio’s scalable, serum-free suspension platform process for lentivirus production
- ElevateBio has built comprehensive cell therapy and viral vector process development, analytics and cGMP manufacturing capabilities to advance therapeutics for its growing number of strategic partners and internal pipeline
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced a poster presentation on ElevateBio BaseCamp’s lentiviral vector production platform at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in Washington, DC. This proprietary process along with supporting analytic methods for lentiviral production is based on transient transfection of serum-free suspension cell growth that is applicable and scalable across different constructs.
“We’re thrilled to debut data from our lentiviral vector platform as we see the need for scalable GMP manufacturing of high-quality lentiviral vectors rapidly increasing with the number of clinical applications,” said Andrew Sandford, President of ElevateBio BaseCamp. “With the expertise we have accumulated at BaseCamp, we developed this platform with a focus on easing the transition from process development to GMP manufacturing to effectively and efficiently scale from preclinical supply to commercial volumes.”
Poster title: A Robust and Scalable Platform Process for GMP Manufacturing of Lentiviral Vectors
Abstract #: 1152
Session title: Vector Product Engineering, Development, or Manufacturing III
Session date/time: Wednesday, May 18, 2022 at 5:30-6:30 p.m. EDT (Hall D)
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
Source: ElevateBio, LLC